<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011021</url>
  </required_header>
  <id_info>
    <org_study_id>0001</org_study_id>
    <nct_id>NCT03011021</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes</brief_title>
  <official_title>Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells With Liraglutide on Autoimmune Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Xiangya Hospital of Central South University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and therapeutic effect of ex-vivo
      expanded umbilical cord blood regulatory T cells adjunct with Liraglutide on autoimmune
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmune Diabetes Mellitus (AIDM) is a subtype of diabetes mellitus caused by autoimmune
      destruction of beta cells in the islet, including Type 1 diabetes and Latent Autoimmune
      Diabetes in Adults (LADA). Insulin has been used as a routine therapy for AIDM to alleviate
      the hyperglycemic status, yet cannot effectively prevent the progressing destruction of beta
      cells or preserve its function. Regulatory T cells expanded from umbilical cord blood
      (UCB-Treg) ex-vivo have shown strong capacity to control immune responses in autoimmune
      diseases, offering a hopeful therapeutic way for AIDM. Glucagon-like peptide (GLP-1) analog
      Liraglutide has been tested in large-scale clinical trial to prove its various benefits for
      beta cells and glucolipid metabolism in Type 2 diabetes and obesity patients. However, its
      clinical application in AIDM is not well-defined so far. The aim of this study is to
      investigate the potential use of Liraglutide with UCB-Treg infusion in AIDM and examine the
      safety and efficacy of this new therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>2 years</time_frame>
    <description>Primary outcome measures will be the number of participants with adverse events, laboratory abnormalities and other signs of toxicity. Particular focus will be on the number and severity of infusion reactions, complications related to infection, and any potential negative impact on the course of diabetes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-peptide</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin dose</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in titer of autoantibodies</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immune cells diversities and quantities.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in autoimmune-related cytokines</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality evaluation</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants with disturbance of emotion, sleep, resting or energy.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <condition>Autoimmune Diabetes</condition>
  <arm_group>
    <arm_group_label>UCB-Treg plus Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single infusion of ex vivo expanded umbilical cord blood derived Treg product (2 x 10^6). Dose escalation of liraglutide up to 1.2 mg will be started 3 days after Treg infusion only if no severe side effects showed. Subjects continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as a routine therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB-Treg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a single infusion of ex vivo expanded Treg product (2 x 10^6). Insulin will be continued as a routine therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive insulin injection as a routine therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.</description>
    <arm_group_label>UCB-Treg plus Liraglutide</arm_group_label>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCB-Treg</intervention_name>
    <description>Receive Treg infusion: 1~5*10^6/kg b.w. in 100ml normal saline</description>
    <arm_group_label>UCB-Treg plus Liraglutide</arm_group_label>
    <arm_group_label>UCB-Treg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Receive insulin following clinician's instruction.</description>
    <arm_group_label>UCB-Treg plus Liraglutide</arm_group_label>
    <arm_group_label>UCB-Treg</arm_group_label>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes according to ADA criteria &lt;3 years.

          -  Age≥ 18 years.

          -  Positive for at least one of the anti-islet autoantibodies: GADA, IA2A, ZnT8A

          -  Fasting or postprandial plasma C-peptide more than 100 pmol/L

          -  Written informed consent from the patient or family representative.

        Exclusion Criteria:

          -  History or family history of medullary thyroid carcinoma or MEN 2 syndrome;

          -  History of chronic or acute pancreatitis;

          -  Allergic to liraglutide or any components in Victoza®;

          -  Hepatic abnormalities (transaminase &gt; 2 times normal);

          -  Renal impairments (serum creatinine &gt;133 umol/L);

          -  Cardiovascular diseases (hypertension, coronary heart disease, etc.);

          -  Presence of anemia (Hb ≤100g/L), leukopenia (&lt;3.5×109/L);

          -  Presence of disorder in coagulation or anticoagulation, or thrombocytopenia (platelets
             &lt;100×109/L);

          -  Presence of acute metabolic disorders; In the case of acute ketone acidosis, with
             blood ketone over 0.3mmol/L and pH lower than 7.30;

          -  Presence of any kind of chronic infection or immune deficiency, including hepatitis B,
             hepatitis C, HIV, syphilis or tuberculosis, etc.;

          -  Chronic use of systemic glucocorticoids or other immunosuppressive agents for over 3
             months;

          -  Any history of malignancy;

          -  Female patients who are pregnant or breastfeeding; any female who is unwilling to use
             a reliable and effective form of contraception for 2 years after recruitment;

          -  Presence of any infectious diseases, including active skin infections, flu, fever,
             upper or lower respiratory tract infections; those who wish to participate in the
             study should keep the infection under control for at least 1 week before receiving
             Treg product infusion;

          -  Any medical condition that, in the opinion of the investigator, will interfere with
             safe participation in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhiguang Zhou, MD/PhD</last_name>
    <phone>86-731-85292154</phone>
    <email>zhouzg@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiguang Zhou, MD/PhD</last_name>
      <phone>86-731-85292154</phone>
      <email>zhouzg@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Milward K, Issa F, Hester J, Figueroa-Tentori D, Madrigal A, Wood KJ. Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells. Transplantation. 2013 Jan 15;95(1):85-93. doi: 10.1097/TP.0b013e31827722ed.</citation>
    <PMID>23263503</PMID>
  </reference>
  <reference>
    <citation>Fan H, Yang J, Hao J, Ren Y, Chen L, Li G, Xie R, Yang Y, Gao F, Liu M. Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood. Immunology. 2012 Jun;136(2):218-30. doi: 10.1111/j.1365-2567.2012.03573.x.</citation>
    <PMID>22348606</PMID>
  </reference>
  <reference>
    <citation>Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011 Jan 20;117(3):1061-70. doi: 10.1182/blood-2010-07-293795. Epub 2010 Oct 15.</citation>
    <PMID>20952687</PMID>
  </reference>
  <reference>
    <citation>Rondas D, D'Hertog W, Overbergh L, Mathieu C. Glucagon-like peptide-1: modulator of β-cell dysfunction and death. Diabetes Obes Metab. 2013 Sep;15 Suppl 3:185-92. doi: 10.1111/dom.12165. Review.</citation>
    <PMID>24003936</PMID>
  </reference>
  <reference>
    <citation>Chang TJ, Tseng HC, Liu MW, Chang YC, Hsieh ML, Chuang LM. Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation. Sci Rep. 2016 Mar 21;6:23403. doi: 10.1038/srep23403. Erratum in: Sci Rep. 2016 May 31;6:26917.</citation>
    <PMID>26997114</PMID>
  </reference>
  <reference>
    <citation>Zoso A, Serafini P, Lanzoni G, Peixoto E, Messinger S, Mantero A, Padilla-Téllez ND, Baidal DA, Alejandro R, Ricordi C, Inverardi L. G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts. PLoS One. 2016 Jun 10;11(6):e0157245. doi: 10.1371/journal.pone.0157245. eCollection 2016.</citation>
    <PMID>27285580</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Zhiguang Zhou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Autoimmune Diabetes</keyword>
  <keyword>Umbilical Cord Blood Regulatory T Lymphocyte</keyword>
  <keyword>Liraglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

